Genetics of hereditary hemochromatosis: a clinical perspective

References

• Feder JN, Gnirke A, Thomas W et al. A novel MHC class 1-like gene is mutated in patients with hereditary hemochromatosis. Nat. Genet.13, 399–408 (1996).
   PubMed Web of Science ®Google Scholar
• Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N. Engl. J. Med.341, 718–724 (1999).
   PubMed Web of Science ®Google Scholar
• Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative hemochromatosis mutations. J. Med. Genet.34, 275–278 (1997).
   PubMed Web of Science ®Google Scholar
• Rossi E, Henderson S, Chin CYB et al. Genotyping as a diagnostic aid in genetic hemochromatosis. J. Gastro. Hepatol.14, 427–430 (1999).
   PubMed Web of Science ®Google Scholar
• Andrews NC. Disorders of iron metabolism. N. Engl. J. Med.341, 1986–1995 (1999).
   PubMed Web of Science ®Google Scholar
• Chua ACG, Graham RM, Trinder D, Olynyk JK. The regulation of cellular iron metabolism. Crit. Rev. Clin. Lab. Sci.44, 413–459 (2007).
   PubMed Web of Science ®Google Scholar
• Adams PC, Barton JC. Haemochromatosis. Lancet370, 1855–1860 (2007).
   PubMedGoogle Scholar
• McKie AT, Barrow D, Latunde-Dada GO et al. An iron-regulated ferric reductase associated with the absorption of dietary iron. Science291, 1755–1759 (2001).
   PubMed Web of Science ®Google Scholar
• McKie AT, Marciani P, Rolfs A et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell5, 299–309 (2000).
   PubMed Web of Science ®Google Scholar
• Vulpe CD, Kuo Y-M, Murphy TL et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse. Nat. Genet.21, 195–199 (1999).
   PubMed Web of Science ®Google Scholar
• Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell72, 19–28 (1993).
   PubMed Web of Science ®Google Scholar
• Chua ACG, Morgan EH, Herbison CE et al. Iron uptake from plasma transferrin in a transferrin receptor 2 mutant mouse model of haemochromatosis type 3. Am. J. Hematol.82, 531 (2007).
   Google Scholar
• Grootveld M, Bell JD, Halliwell B, Aruoma OI, Bomford A, Sadler PJ. Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy. J. Biol. Chem.264, 4417–4422 (1989).
   PubMed Web of Science ®Google Scholar
• Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci.23, 185–192 (2000).
   PubMedGoogle Scholar
• Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin, a new iron regulatory peptide. Blood Cells Mol. Dis.29, 327–335 (2002).
   PubMed Web of Science ®Google Scholar
• Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science306, 2090–2093 (2004).
   PubMed Web of Science ®Google Scholar
• Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology48(3), 991–1001 (2008).
   PubMed Web of Science ®Google Scholar
• Nicolas G, Chauvet C, Viatte L et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest.110, 1037–1044 (2002).
   PubMed Web of Science ®Google Scholar
• Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine (Baltimore)34, 381–430 (1955).
   PubMed Web of Science ®Google Scholar
• Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol. Dis.330, 288–297 (2003).
   Google Scholar
• Olynyk JK. Hereditary hemochromatosis: diagnosis and management in the gene era. Liver19, 73–80 (1999).
   PubMedGoogle Scholar
• Gochee PA, Powell LW, Cullen DJ, Du Sart D, Rossi E, Olynyk JK. A population-based study of the biochemical and clinical expression of the H63D hemochromatosis mutation. Gastroenterology122, 646–651 (2002).
   PubMed Web of Science ®Google Scholar
• Pointon JJ, Wallace D, Merryweather-Clarke AT, Robson KJH. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet. Test.4, 151–161 (2000).
   PubMedGoogle Scholar
• Camaschella C. Juvenile hemochromatosis. Baillieres Clin. Gastroenterol.12, 227–235 (1998).
   PubMed Web of Science ®Google Scholar
• Pietrangelo A. Non-HFE hemochromatosis. Semin. Liv. Dis.450–460 (2005).
   PubMedGoogle Scholar
• Papanikolaou G, Samuels ME, Ludwig EH et al. Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemochromatosis. Nat. Genet.36, 77–82 (2004).
   PubMed Web of Science ®Google Scholar
• Rivard SR, Lanzara C, Grimard D et al. Juvenile hemochromatosis locus maps to chromosome 1q in a French Canadian population. Eur. J. Hum. Genet.11, 585–589 (2003).
   PubMed Web of Science ®Google Scholar
• Lanzara SP, Roetto A, Caraio F et al. Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood103(11), 4317–4321 (2004).
   PubMed Web of Science ®Google Scholar
• Camaschella C, Roetto A, Calã A et al. The gene TFR2 is mutated in a new type of hemochromatosis mapping to 7q22. Nat. Genet.25, 14–15 (2000).
   PubMed Web of Science ®Google Scholar
• De Gobbi M, Barilaro MR, Garozzo G, Sbaiz L, Alberti F, Camaschella C. TFR2 Y250X mutation in Italy. Br. J. Haematol.114, 243–244 (2001).
   PubMedGoogle Scholar
• Roetto A, Totaro A, Piperno A et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood97, 2555–2560 (2001).
   PubMed Web of Science ®Google Scholar
• Girelli D, Bozzini C, Roetto A et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology122, 1295–1302 (2002).
   PubMed Web of Science ®Google Scholar
• Koyama C, Wakusawa S, Hayashi H et al. Two novel mutations, L490R and V561X, of the transferrin receptor 2 gene in Japanese patients with hemochromatosis. Haematologica90, 302–307 (2005).
   PubMedGoogle Scholar
• Le Gac G, Mons F, Jacolot S, Scotet V, Ferec C, Frebourg T. Early onset hereditary hemochromatosis resulting from a novel TFR2 gene nonsense mutation (R105X) in two siblings of north French descent. Br. J. Haematol.125, 674–678 (2004).
   PubMed Web of Science ®Google Scholar
• Mattman A, Huntsman D, Lockitch G et al. Transferrin receptor 2 (TfR2) and HFE mutational analysis in non-C282Y iron overload: identification of a novel TfR2 mutation. Blood100, 1075–1077 (2002).
   PubMedGoogle Scholar
• Montosi G, Donovan A, Totaro A et al. Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. J. Clin. Invest.108, 619–623 (2001).
   PubMed Web of Science ®Google Scholar
• Njajou OT, Vaessen N, Joosse M et al. A mutation in SLC11A3 is associated with autosomal dominant hemochromatosis. Nat. Genet.28, 213–214 (2001).
   PubMed Web of Science ®Google Scholar
• Rivers CA, Barton JC, Gordeuk VR et al. Association of ferroportin Q248H polymorphism with elevated levels of serum ferritin in African Americans in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. Blood Cells Mol. Dis.38,247–252 (2007).
   PubMedGoogle Scholar
• Arden KE, Wallace DF, Dixon JL et al. A novel mutation in ferroportin 1 is associated with hemochromatosis in a Solomon Islands patient. Gut52, 1215–1217 (2003).
   PubMedGoogle Scholar
• Bach V, Remacha A, Altes A, Barcelo MJ, Molina MA, Baiget M. Autosomal dominant hereditary hemochromatosis associated with two novel ferroportin 1 mutations in Spain. Blood Cells Mol. Dis.36,41–45 (2006).
   PubMedGoogle Scholar
• Gordeuk VR, Caleffi A, Corradini E et al. Iron overload in Africans and African–Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. Blood Cells Mol. Dis.31, 299–304 (2003).
   PubMedGoogle Scholar
• Hetet G, Devaux I, Soufir N, Grandchamp B, Beaumont C. Molecular analyses of patients with hyperferritinemia and normal serum iron values reveal both L ferritin IRE and 3 new ferroportin (slc11A3) mutations. Blood102, 1904–1910 (2003).
   PubMed Web of Science ®Google Scholar
• Jouanolle A-M, Douabin-Gicquel V, Halimi C et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J. Hepatol.39, 286–289 (2003).
   PubMedGoogle Scholar
• De Domenico I, Ward DM, Nemeth E et al. The molecular basis of ferroportin-linked hemochromatosis. Proc. Natl Acad. Sci. USA102, 8955–8960 (2005).
   PubMed Web of Science ®Google Scholar
• Drakesmith H, Schimanski LM, Ormerod E et al. Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin. Blood106, 1092–1097 (2005).
   PubMed Web of Science ®Google Scholar
• Schimanski LM, Drakesmith H, Merryweather-Clarke AT et al.In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations. Blood105, 4096–4102 (2005).
   PubMed Web of Science ®Google Scholar
• Chua ACG, Herbison CE, Drake SF et al. The role of HFE in transferrin-bound iron uptake by hepatocytes Hepatology47(5), 1737–1744 (2008).
   PubMedGoogle Scholar
• Siah CW, Trinder D, Olynyk JK. Iron overload. Clin. Chim. Acta358, 24–36 (2005).
   PubMedGoogle Scholar
• Gitlin JD. Aceruloplasminemia. Pediatr. Res.44, 271–276 (1998).
   PubMed Web of Science ®Google Scholar
• Hayashi A, Wada Y, Suzuki T, Shimizu A. Studies on familial hypotransferrinemia: unique clinical course and molecular pathology. Am. J. Hum. Genet.53, 201–213 (1993).
   PubMed Web of Science ®Google Scholar
• Whitington PF. Neonatal hemochromatosis: a congenital alloimmune hepatitis. Semin. Liver Dis.243–250 (2007).
   PubMedGoogle Scholar
• Adams PC, Reboussin DM, Barton JC et al. Hemochromatosis and iron-overload screening in a racially diverse population. N. Engl. J. Med.352, 1769–1778 (2005).
   PubMed Web of Science ®Google Scholar
• Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T. Penetrance of 845G A (C282Y) HFE hereditary hemochromatosis mutation in the USA. Lancet359, 211–218 (2002).
   PubMed Web of Science ®Google Scholar
• Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG. Hemochromatosis mutations in the general population: iron overload progression rate. Blood103, 2914–2919 (2004).
   PubMed Web of Science ®Google Scholar
• Delatycki MB, Allen KJ, Nisselle AE et al. Use of community genetic screening to prevent HFE-associated hereditary hemochromatosis. Lancet366, 314–316 (2005).
   PubMedGoogle Scholar
• Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE. Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin. Proc.79(3), 309–313 (2004).
   PubMed Web of Science ®Google Scholar
• Yamashita C, Adams PC. Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level. Clin. Gastroenterol. Hepatol.1(5), 388–391 (2003).
   PubMed Web of Science ®Google Scholar
• Powell LW, Dixon JL, Ramm GA et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Int. Med.166, 294–301 (2006).
   PubMedGoogle Scholar
• Gurrin LC, Osborne NJ, Constantine CC et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastroenterology135(6), 1945–1952 (2008).
   PubMed Web of Science ®Google Scholar
• Barton JC, McDonnell SM, Adams PC et al. Management of hemochromatosis. Hemochromatosis Management Working Group. Ann. Intern. Med.129, 932–939 (1998).
   PubMed Web of Science ®Google Scholar
• Allen KJ, Gurrin LC, Constantine CC et al. Iron-overload-related disease in HFE hereditary hemochromatosis. N. Engl. J. Med.358(3), 221–230 (2008).
   PubMed Web of Science ®Google Scholar
• Barton JC, Wiener HW, Acton RT, Go RC. HLA haplotype A*03-B*07 in hemochromatosis probands with HFE C282Y homozygosity: frequency disparity in men and women and lack of association with severity of iron overload. Blood Cells Mol. Dis.34, 38–47 (2005).
   PubMed Web of Science ®Google Scholar
• Cruz E, Melo G, Lacerda R, Almeida S, Porto G. The CD8+ T-lymphocyte profile as a modifier of iron overload in HFE hemochromatosis: an update of clinical and immunological data from 70 C282Y homozygous subjects. Blood Cells Mol. Dis.37(1), 33–39 (2006).
   PubMed Web of Science ®Google Scholar
• Lim EM, Rossi E, De Boer WB, Reed WD, Jeffrey GP. Hepatic iron loading in patients with compound heterozygous HFE mutations. Liver Int.24, 631–636 (2004).
   PubMed Web of Science ®Google Scholar
• Gurrin LC, Bertalli, Dalton GW et al. HFE-compound heterozygotes are at low risk of hemochromatosis-related morbidity (In Press) (2009).
   Google Scholar
• Walsh A, Dixon JL, Ramm GA et al. The clinical relevance of compound heterozygosity for the C282Y and H63D substitutions in hemochromatosis. Clin. Gastroenterol. Hepatol.114(5), 1003–1008 (1998).
   Google Scholar
• Ayonrinde OT, Milward EA, Chua AC, Trinder D, Olynyk JK. Clinical perspectives on hereditary hemochromatosis. Crit. Rev. Clin. Lab. Sci.45(5), 451–484 (2008).
   PubMed Web of Science ®Google Scholar
• McLaren CE, McLachlan GJ, Halliday JW et al. Distribution of transferrin saturation in an Australian population: relevance to the early diagnosis of hemochromatosis. Gastroenterology114, 543–549 (1998).
   PubMed Web of Science ®Google Scholar
• Bacon BR. Hemochromatosis: diagnosis and management. Gastroenterology120, 718–725 (2001).
   PubMed Web of Science ®Google Scholar
• Bomford A. Genetics of hemochromatosis. Lancet360, 1673–1681 (2002).
   PubMed Web of Science ®Google Scholar
• Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR. Screening for hereditary hemochromatosis: a systematic review for the US Preventive Services Task Force. Ann. Intern. Med.145, 209–223 (2006).
   PubMed Web of Science ®Google Scholar
• Waalen J, Felitti VJ, Gelbart T, Beutler E. Screening for hemochromatosis by measuring ferretin levels: a more effective approach. Blood111, 3373–3376 (2008).
   PubMed Web of Science ®Google Scholar
• Olynyk JK, St Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. Am. J. Gastroenterol.100, 837–841 (2005).
   PubMed Web of Science ®Google Scholar
• Powell LW, Dixon JL, Ramm GA et al. Screening for hemochromatosis in asymptomatic subjects with or without a family history. Arch. Intern. Med.166, 294–301 (2006).
   PubMedGoogle Scholar
• Adams PC, Reboussin DM, Leiendecker-Foster C et al. Comparison of the unsaturated iron-binding capacity with transferrin saturation as a screening test to detect C282Y homozygotes for hemochromatosis in 101,168 participants in the hemochromatosis and iron overload screening (HEIRS) study. Clin. Chem.51, 1048–1052 (2005).
   PubMedGoogle Scholar
• Olynyk JK, Gan E, Tan T. Predicting iron overload in hyperferretinemia. Clin. Gastrol. Hepatol.7(3), 359–362 (2009).
   PubMedGoogle Scholar
• Vartsky D, Ellis KJ, Hull DM, Cohn SH. Nuclear resonant scattering of g rays – a new technique for in vivo measurement of body iron stores. Phys. Med. Biol.24, 689–701 (1979).
   PubMedGoogle Scholar
• Leung AW, Steiner RE, Young IR. NMR imaging of the liver in 2 cases of iron overload. J. Comput. Assist. Tomogr.8, 446–449 (1984).
   PubMedGoogle Scholar
• Brittenham GM, Badman DG. Noninvasive measurement of iron: report of an NIDDK workshop. Blood101, 15–19 (2003).
   PubMed Web of Science ®Google Scholar
• Adams PC. Review article: the modern diagnosis and management of haemochromatosis. Aliment. Pharmacol. Ther.23, 1681–1691 (2006).
   PubMedGoogle Scholar
• Alustiza JM, Artetxe J, Castiella A et al. MR quantification of hepatic iron concentration. Radiology230, 479–484 (2004).
   PubMed Web of Science ®Google Scholar
• St Pierre TG, Clark PR, Chua-Anusorn W et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood105, 855–861 (2005).
   PubMed Web of Science ®Google Scholar
• Gandon Y, Olivie D, Guyader D et al. Non-invasive assessment of hepatic iron stores by MRI. Lancet363, 357–362 (2004).
   PubMed Web of Science ®Google Scholar
• Guyader D, Jacquelinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology115, 929–936 (1998).
   PubMed Web of Science ®Google Scholar
• Asberg A, Hveem K, Thorstensen K et al. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons. Scand. J. Gastroenterol.36, 1108–1115 (2001).
   PubMed Web of Science ®Google Scholar
• Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. HFE genotype in patients with hemochromatosis and other liver diseases. Ann. Intern. Med.130, 953–962 (1999).
   PubMedGoogle Scholar
• Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: relationship to HFE mutations. Am. J. Gastroenterol.95, 1788–1793 (2000).
   PubMedGoogle Scholar
• Tavill AS. Diagnosis and management of hemochromatosis. Hepatology33, 1321–1328 (2001).
   PubMed Web of Science ®Google Scholar
• Crawford DH, Murphy DL, Ramm LE et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis Hepatology49(2), 418–425 (2009).
   PubMedGoogle Scholar
• Burke W, Thomson E, Khoury MJ et al. Hereditary hemochromatosis: gene discovery and its implications for population-based screening. JAMA280, 172–178 (1998).
   PubMed Web of Science ®Google Scholar
• Alper JS, Geller LN, Barash CI, Billings PR, Laden V, Natowicz MR. Genetic discrimination and screening for hemochromatosis. J. Public Health Policy15, 345–358 (1994).
   PubMedGoogle Scholar
• Galhenage SP, Viiala CH, Olynyk JK. Screening for hemochromatosis: patients with liver disease, families and population. Curr. Gastroenterol. Rep.6, 44–51 (2004).
   PubMedGoogle Scholar
• Smith PM, Godfrey BE, Williams R. Iron absorption in idiopathic haemochromatosis and its measurement using a whole-body counter. Clin. Sci.37(2), 519–531 (1969).
   PubMed Web of Science ®Google Scholar
• Lynch SR, Skikne BS, Cook JD. Food iron absorption in idiopathic hemochromatosis. Blood74(6), 2187–2193 (1989).
   PubMed Web of Science ®Google Scholar
• McCune CA, Ravine D, Carter K et al. Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients. Gut55(4), 554–562 (2006).
   PubMed Web of Science ®Google Scholar
• Milward EA, Baines SK, Knuiman MW et al. Noncitrus fruits as novel dietary environmental modifiers of iron stores in people with or without HFE gene mutations. Mayo Clin. Proc.83(5), 543–549 (2008).
   PubMed Web of Science ®Google Scholar
• Cade JE, Moreton JA, O’Hara B et al. Diet and genetic factors associated with iron status in middle-aged women. Am. J. Clin. Nutr.82(4), 813–820 (2005).
   PubMed Web of Science ®Google Scholar
• Van der A DL, Peeters PH, Grobbee DE, Roest M, Voorbij HA, van der Schouw YT. HFE genotypes and dietary heme iron: no evidence of strong gene-nutrient interaction on serum ferritin concentrations in middle-aged women. Nutr. Metab. Cardiovasc. Dis.16(1), 60–68 (2006).
   PubMedGoogle Scholar
• Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology6(1), 24–29 (1986).
   PubMed Web of Science ®Google Scholar
• Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW. The effect of haemochromatosis genotype and life-style factors on iron and red cell indices in a community population. Clin. Chem.47, 202–208 (2001).
   PubMed Web of Science ®Google Scholar
• Moirand R, Lescoat G, Delamaire D et al. Increase in glycosylated and nonglycosylated serum ferritin in chronic alcoholism and their evolution during alcohol withdrawal. Alcohol Clin. Exp. Res.15(6), 963–969 (1991).
   PubMed Web of Science ®Google Scholar
• Scotet V, Merour MC, Mercier AY et al. Hereditary hemochromatosis: effect of excessive alcohol consumption on disease expression in patients homozygous for the C282Y mutation. Am. J. Epidemiol.158(2), 129–134 (2003).
   PubMed Web of Science ®Google Scholar
• Fletcher LM, Dixon JL, Purdie DM, Powell LW, Crawford DH. Excess alcohol greatly increases the prevalence of cirrhosis in hereditary hemochromatosis. Gastroenterology122(2), 281–289 (2002).
   PubMed Web of Science ®Google Scholar
• Bridle K, Cheung TK, Murphy T et al. Hepcidin is down-regulated in alcoholic liver injury: implications for the pathogenesis of alcoholic liver disease. Alcohol Clin. Exp. Res.30(1), 106–112 (2006).
   PubMed Web of Science ®Google Scholar
• Harrison-Findik DD, Schafer D, Klein E et al. Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J. Biol. Chem.281, 22974–22982 (2006).
   PubMed Web of Science ®Google Scholar
• Whitfield JB, Cullen LM, Jazwinska EC et al. Effects of HFE C282Y and H63D polymorphisms and polygenic background on iron stores in a large community sample of twins. Am. J. Hum. Genet.66(4), 1246–1258 (2000).
   PubMed Web of Science ®Google Scholar
• Merryweather-Clarke AT, Cadet E, Bomford A et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum. Mol. Genet.12(17), 2241–2247 (2003).
   PubMed Web of Science ®Google Scholar
• Jacolot S, Le Gac G, Scotet V, Quere I, Mura C, Ferec C. HAMP as a modifier gene that increases the phenotypic expression of the HFE pC282Y homozygous genotype. Blood103(7), 2835–2840 (2004).
   PubMed Web of Science ®Google Scholar
• Le Gac G, Scotet V, Ka C et al. The recently identified type 2A juvenile haemochromatosis gene (HJV), a second candidate modifier of the C282Y homozygous phenotype. Hum. Mol. Genet.13(17), 1913–1918 (2004).
   PubMed Web of Science ®Google Scholar
• Piperno A, Mariani R, Arosio C et al. Haemochromatosis in patients with β-thalassaemia trait. Br. J. Haematol.111(3), 908–914 (2000).
   PubMed Web of Science ®Google Scholar
• Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med.13(9), 1096–1101 (2007).
   PubMed Web of Science ®Google Scholar
• Milet J, Dehais V, Bourgain C et al. Common variants in the BMP2, BMP4, and HJV genes of the hepcidin regulation pathway modulate HFE hemochromatosis penetrance. Am. J. Hum. Genet.81(4), 799–807 (2007).
   PubMed Web of Science ®Google Scholar
• Lee PL, Gelbart T, West C, Halloran C, Felitti V, Beutler E. A study of genes that may modulate the expression of hereditary hemochromatosis: transferrin receptor-1, ferroportin, ceruloplasmin, ferritin light and heavy chains, iron regulatory proteins (IRP)-1 and -2, and hepcidin. Blood Cells Mol. Dis.27(5), 783–802 (2001).
   PubMed Web of Science ®Google Scholar
• Lee P, Gelbart T, West C, Halloran C, Beutler E. Seeking candidate mutations that affect iron homeostasis. Blood Cells Mol. Dis.29(3), 471–487 (2002).
   PubMed Web of Science ®Google Scholar
• Benyamin B, McRae AF, Zhu G et al. Variants in TF and HFE explain approximately 40% of genetic variation in serum-transferrin levels. Am. J. Hum. Genet.84(1), 60–65 (2009).
   PubMedGoogle Scholar
• Van Vlierberghe H, Langlois M, Delanghe J et al. Haptoglobin phenotype 2-2 overrepresentation in Cys282Tyr hemochromatotic patients. J. Hepatol.35(6), 707–711 (2001).
   PubMed Web of Science ®Google Scholar
• Piperno A, Arosio C, Fargion S et al. The ancestral hemochromatosis haplotype is associated with a severe phenotype expression in Italian patients. Hepatology24(1), 43–46 (1996).
   PubMed Web of Science ®Google Scholar
• Pratiwi R, Fletcher LM, Pyper WR et al. Linkage disequilibrium analysis in Australian haemochromatosis patients indicates bipartite association with clinical expression. J. Hepatol.31(1), 39–46 (1999).
   PubMed Web of Science ®Google Scholar
• Adams PC, Agnew S. Alcoholism in hereditary hemochromatosis revisited: prevalence and clinical consequences among homozygous siblings. Hepatology23(4), 724–727 (1996).
   PubMed Web of Science ®Google Scholar
• Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology124(2), 318–326 (2003).
   PubMed Web of Science ®Google Scholar
• Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J. Hepatol.36(5), 687–691 (2002).
   PubMed Web of Science ®Google Scholar
• Powell EE, Ali A, Clouston AD et al. Steatosis is a cofactor in liver injury in hemochromatosis. Gastroenterology129(6), 1937–1943 (2005).
   PubMed Web of Science ®Google Scholar
• Valenti L, Fracanzani AL, Dongiovanni P et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case–control study. Am. J. Gastroenterol.102(6), 1251–1258 (2007).
   PubMed Web of Science ®Google Scholar
• Di Martino V, Lebray P, Myers RP et al. Progression of liver fibrosis in women infected with hepatitis C: long-term benefit of estrogen exposure. Hepatology40(6), 1426–1433 (2004).
   PubMed Web of Science ®Google Scholar
• Loréal O, Deugnier Y, Moirand R et al. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J. Hepatol.16(1–2) 122–127 (1992).
   PubMed Web of Science ®Google Scholar
• Shimizu I. Impact of oestrogens on the progression of liver disease. Liver Int.23(1), 63–69 (2003).
   PubMed Web of Science ®Google Scholar
• Osterreicher CH, Datz C, Stickel F et al. TGF-β1 codon 25 gene polymorphism is associated with cirrhosis in patients with hereditary hemochromatosis. Cytokine31(2), 142–148 (2005).
   PubMed Web of Science ®Google Scholar
• Fargion S, Valenti L, Dongiovanni P et al. Tumor necrosis factor a promoter polymorphisms influence the phenotypic expression of hereditary hemochromatosis. Blood97(12), 3707–3712 (2001).
   PubMed Web of Science ®Google Scholar
• Distante S, Elmberg M, Foss Haug KB et al. Tumour necrosis factor a and its promoter polymorphisms’ role in the phenotypic expression of hemochromatosis. Scand. J. Gastroenterol.38(8), 871–877 (2003).
   PubMed Web of Science ®Google Scholar
• Beutler E, Gelbart T. Tumor necrosis factor a promoter polymorphisms and liver abnormalities of homozygotes for the 845G>A(C282Y) hereditary hemochromatosis mutation. Letter. Blood100(6), 2268–2269 (2002).
   PubMed Web of Science ®Google Scholar
• Marra F, DeFranco R, Grappone C et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am. J. Pathol.152(2), 423–430 (1998).
   PubMed Web of Science ®Google Scholar
• Mühlbauer M, Bosserhoff AK, Hartmann A et al. A novel MCP-1 gene polymorphism is associated with hepatic MCP-1 expression and severity of HCV-related liver disease. Gastroenterology125(4), 1085–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Stickel F, Osterreicher CH, Datz C et al. Prediction of progression to cirrhosis by a glutathione S-transferase P1 polymorphism in subjects with hereditary hemochromatosis. Arch. Intern. Med.165(16), 1835–1840 (2005).
   PubMedGoogle Scholar
• Osterreicher CH, Datz C, Stickel F et al. Association of myeloperoxidase promotor polymorphism with cirrhosis in patients with hereditary hemochromatosis. J. Hepatol.42(6), 914–919 (2005).
   PubMed Web of Science ®Google Scholar
• Valenti L, Conte D, Piperno A et al. The mitochondrial superoxide dismutase A16V polymorphism in the cardiomyopathy associated with hereditary haemochromatosis. J. Med. Genet.41, 946–950 (2004).
   PubMed Web of Science ®Google Scholar
• Bulaj ZJ, Ajioka RS, Phillips JD et al. Disease-related conditions in relatives of patients with hemochromatosis. N. Engl. J. Med.343(21), 1529–1535 (2000).
   PubMed Web of Science ®Google Scholar